Skip to content

[Association between initial antiretroviral therapy regimens and virological outcomes in HIV-infected individuals in Taizhou, Zhejiang Province, 2006-2025].

Aug 2026 · Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi · Vol 47 8, pp. 1471-1477 · 0 citations
Medicine

TL;DR

Among HIV-infected individuals in Taizhou who received NVP-based initial ART regimens between 2006 and 2025, the risk of virological failure was higher than among those who received EFV-based or INSTI/PI-based regimens, suggesting that when formulating ART regimens in clinical practice, the use of regimens based on EFV or INSTI/PI should be given priority.

View source

Similar papers

Open access Oct 2026

HIV-1 drug resistance and associated risk factors in antiretroviral therapy failure: a 2022–2024 surveillance in Huzhou, China

Characterizing acquired drug resistance (ADR) profiles among individuals experiencing antiretroviral therapy (ART) failure is critical for optimizing clinical management. This study aimed to delineate the HIV-1 drug resistance landscape, specific resistance-associated mutations, and epidemiological determi...

Zhong-Hao Lu, Yi-Jie Wu, Y. Zha et al. · 0 citations
Open access Oct 2026

Low Prevalence of HIV-1 Antiretroviral Resistance Among Patients Experiencing Virological Failure on Dolutegravir-Based Regimens: A Prospective Cohort Study in Bunia, Democratic Republic of the Congo

The adoption and widespread use of dolutegravir (DTG)-based antiretroviral therapy (ART) are key strategies for achieving global 2030 targets, though emerging resistance threatens long-term success. This study evaluated HIV-1 drug resistance mutations among participants experiencing virological failure in Bunia, Democr...

Alex Liripa Kwendra, A. Mouinga-Ondémé, J. Engone-Ondo et al. · 0 citations
Open access Sep 2026

Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study

Although exposure prophylaxis was not linked to overall PDR, its association with emtricitabine-specific resistance highlighted the need for strengthened HIV-1 testing prior to prophylaxis initiation and enhanced resistance surveillance, but they require confirmation in future studies.

W. Cheng, Qin Fan, Jia-Feng Zhang et al. · 0 citations
Open access Oct 2026

Clinical and immunological correlates of CXCR4 coreceptor use in people with HIV-1 receiving antiretroviral therapy in the Netherlands: a multicentre cohort study.

BACKGROUND CXCR4-using (X4) viruses are associated with faster disease progression in untreated HIV-1 infection, although their clinical, virological, and immunological correlates during suppressive antiretroviral therapy are not well characterised. We aimed to assess the associations between X4 coreceptor use and clin...

Kavita Mehta, Twan Otten, Victoria Rios-Vazquez et al. · 0 citations
Open access Sep 2026

Prevalence and transmission of pretreatment drug resistance and acquired drug resistance among people living with HIV-1 in Chongqing, China, 2014–2024

Different patterns of drug resistance mutations associated with different ART regimens were observed when comparing PDR and ADR populations, underscoring the necessity of sustained, routine surveillance of PDR and ADR and providing strong support to guide personalized regimen selection and reduce the risk of virologica...

Wen-Wan Gao, Jun-Gang Li, Mei Li et al. · 0 citations
Open access Sep 2026

Genotype-guided antiretroviral therapy outcomes in routine clinical practice: a retrospective study of HIV viral load suppression at 6 and 12 months in Uganda.

This study assessed virological outcomes following genotype-guided antiretroviral therapy (GART). We conducted a retrospective cohort of 235 PLHIV (2021-2023) post-GART after virological failure, analyzing baseline characteristics, 6- and 12-month viral load outcomes, and suppression factors using descriptive statistic...

Collins Ankunda, Jude Emunyu, S. Namasambi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.